Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 16Active not recruiting 7Not yet recruiting 2Completed 2Withdrawn 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1

Interventions

venetoclax 38Azacitidine 24fludarabine 20Cytarabine 18Cyclophosphamide 16Specimen Handling 14blinatumomab 13Biopsy 12Busulfan 8Dexamethasone 7Melphalan 6Daunorubicin 6Whole-Body Irradiation 5Vincristine 5Thiotepa 5Methotrexate 5Decitabine 5gilteritinib 4daratumumab 4Tacrolimus 4Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Imatinib Mesylate 4Idarubicin 4Exercise 4Blood Specimen Collection 4zanubrutinib 3selinexor 3ruxolitinib 3revumenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × pirtobrutinib × Other hematologic neoplasm × Clear all
NCT07624799 2026-06-03

PACIFIC

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
82 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT07516093 2026-04-08

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Nurix Therapeutics, Inc.

Phase 3 Not yet recruiting
620 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡